Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Larimar Therapeutics (NASDAQ:LRMR)

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Larimar Therapeutics (NASDAQ:LRMR)

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in the ongoing open label extension (OLE) study Larimar is continuing to enroll adolescent patients and plans to initiate a cohort of children 2-11 years old in 1H 2025 Long-term 50 mg data from adults in OLE study and available adolescent PK run-in d…

Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for Friedreich’s ataxia (FA), marking an important step in expanding the clinical evaluation of its investigational therapy, nomlabofusp, to younger patients. Adolescents are receiving a weight-adjusted dose equivalent to the 50 mg dose used in adults. Upon completing the PK run-in study, eligible…